文献速递流行病学与生物统计

乳糜泻筛查:美国预防服务工作组证据报告与系统综述

Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2017-01-01

本证据报告为美国预防服务工作组评估无症状成人、青少年及3岁以上儿童乳糜泻筛查的获益与危害。未发现筛查相关的随机对照试验;仅有的两项无症状人群血清学检测研究报告灵敏度较低(57%和71%)。一项小型芬兰治疗试验显示无麸质饮食对胃肠道症状有小幅改善,但多数生活质量指标无差异。整体证据不足以回答多数关键问题,需进一步研究。

要点

  • 未发现评估乳糜泻筛查获益与危害的随机对照试验。
  • IgA组织转谷氨酰胺酶抗体诊断准确性高,灵敏度和特异度均>90%。
  • 无症状人群中血清学检测灵敏度较低(57%和71%)。

核心结论

  • 虽然有一些关于乳糜泻检测诊断准确性的证据,但几乎或没有证据可回答无症状个体乳糜泻筛查获益与危害的多数关键问题。
  • 需要更多研究来了解乳糜泻筛查和治疗的有效性、筛查检测在无症状人群中的准确性以及最佳筛查策略。

研究设计与样本

  • 本证据报告为美国预防服务工作组进行的系统综述,检索Ovid MEDLINE、Cochrane对照试验中心注册库和Cochrane系统综述数据库至2016年6月14日。
  • 纳入标准为:关于筛查与不筛查乳糜泻临床获益与危害、或筛查发现乳糜泻治疗与不治疗的随机临床试验及队列或病例对照研究;关于乳糜泻血清学检测诊断准确性的研究。
  • 数据提取由一名研究者完成,第二名研究者核对准确性,两名研究者独立使用预定义标准评估研究质量。
  • 未进行荟萃分析合并。
  • 共纳入1篇系统综述和3项原始研究。

主要发现

  • 未发现乳糜泻筛查的随机对照试验。
  • 一项近期高质量系统综述(纳入56项原始研究和12项既往系统综述,原始研究样本量从62至超过12000名参与者)发现IgA组织转谷氨酰胺酶抗体诊断乳糜泻准确性高(灵敏度和特异度均>90%)。
  • IgA肌内膜抗体检测与高特异度相关。
  • 仅有两项在无症状人群中进行的乳糜泻血清学检测研究(分别涉及62例和158例患者),报告灵敏度较低(57%和71%)。
  • 一项公平质量的小型芬兰治疗试验(n=40)纳入基于血清学阳性筛查发现的无症状成人乳糜泻患者,发现开始无麸质饮食与不进行无麸质饮食相比,在1年时胃肠道症状有小幅改善(在1至7分量表上差异小于1分),多数生活质量指标无差异;试验期间无因不良事件退出,未报告其他危害。

关键数值与推荐

  • IgA组织转谷氨酰胺酶抗体诊断乳糜泻的灵敏度和特异度均>90%。
  • IgA肌内膜抗体检测与高特异度相关。
  • 无症状人群中血清学检测灵敏度分别为57%和71%。
  • 芬兰治疗试验中无麸质饮食与不进行无麸质饮食相比,胃肠道症状在1至7分量表上差异小于1分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未发现乳糜泻筛查的随机对照试验。
  • 仅有两项血清学检测研究在无症状人群中进行,分别涉及62例和158例患者,报告灵敏度较低(57%和71%)。
  • 芬兰治疗试验为小型(n=40)、公平质量研究。
  • 几乎或没有证据可回答无症状个体乳糜泻筛查获益与危害的多数关键问题。
  • 需要更多研究来了解乳糜泻筛查和治疗的有效性、筛查检测在无症状人群中的准确性以及最佳筛查策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Silent or subclinical celiac disease may result in potentially avoidable adverse health consequences. OBJECTIVE: To review the evidence on benefits and harms of screening for celiac disease in asymptomatic adults, adolescents, and children 3 years and older for the US Preventive Services Task Force. DATA SOURCES: Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews, searched to June 14, 2016. STUDY SELECTION: Randomized clinical trials and cohort or case-control studies on clinical benefits and harms of screening vs no screening for celiac disease or treatment vs no treatment for screen-detected celiac disease; studies on diagnostic accuracy of serologic tests for celiac disease. DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data, a second checked data for accuracy, and 2 investigators independently assessed study quality using predefined criteria. MAIN OUTCOMES AND MEASURES: Cancer incidence, gastrointestinal outcomes, psychological outcomes, child growth outcomes, health outcomes resulting from nutritional deficiencies, quality of life, mortality, and harms of screening. No meta-analytic pooling was done. RESULTS: One systematic review and 3 primary studies met inclusion criteria. No trials of screening for celiac disease were identified. One recent, good-quality systematic review of 56 original studies and 12 previous systematic reviews (sample sizes of primary studies ranging from 62 to more than 12 000 participants) found IgA tissue transglutaminase was associated with high accuracy (sensitivity and specificity both >90%) for diagnosing celiac disease. IgA endomysial antibodies tests were associated with high specificity. Only 2 studies of serologic tests for celiac disease involving 62 and 158 patients were conducted in asymptomatic populations and reported lower sensitivity (57% and 71%). One fair-quality, small (n = 40) Finnish treatment trial of asymptomatic adults with screen-detected celiac disease based on positive serologic findings found initiation of a gluten-free diet associated with small improvement in gastrointestinal symptoms compared with no gluten-free diet (difference less than 1 point on a scale of 1 to 7) at 1 year, with no differences on most measures of quality of life. No withdrawals due to adverse events occurred during the trial; no other harms were reported. No studies were identified that addressed the other outcomes. CONCLUSIONS AND RELEVANCE: Although some evidence was found regarding diagnostic accuracy of tests for celiac disease, little or no evidence was identified to inform most of the key questions related to benefits and harms of screening for celiac disease in asymptomatic individuals. More research is needed to understand the effectiveness of screening and treatment for celiac disease, accuracy of screening tests in asymptomatic persons, and optimal screening strategies.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Chou R, Bougatsos C, Blazina I, et al. Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017. PMID: 28350935. doi:10.1001/jama.2016.10395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。